Caelyx: treatment for relapsing ovarian cancer.

Abstract

Although there have been significant improvements in the first-line treatment of ovarian cancer, the options for patients who relapse have been limited. Caelyx is a new treatment using long-circulating liposomes to target delivery of doxorubicin to the tumour. This article reviews the treatment of ovarian cancer and looks at the place of Caelyx as a new second-line treatment option.

• Authors: S R Johnston, S Kaye
• Journal: Hospital medicine (London, England : 1998) (Hosp Med) Vol. 62 Issue 10 Pg. 611-6 (Oct 2001) ISSN: 1462-3935 [Print] England
• PMID: 11688123 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Liposomes
• Doxorubicin

Topics

• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Doxorubicin (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Liposomes
• Neoplasm Recurrence, Local (drug therapy)
• Ovarian Neoplasms (drug therapy)